A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The primary study objective is to assess the safety of afamelanotide while the secondary
objective is to assess whether the therapy affects the size of the penumbra, by increasing
blood flow, restoring oxygen supply to the brain, and reducing the amount of cerebral oedema
(fluid) which is seen as a result of the stroke. Positive findings would indicate that the
drug is able to support brain tissue-at-risk and provide overall neuroprotection and benefit
to stroke patients.